As a phase-1 clinical trial with a humanized anti-uPARAP ADC has now been initiated in a different cancer indication, as mentioned above, this underscores the clinical relevance of our work, which may pave the way for expanding treatment strategies for mesothelioma, a disease with an extraordinary need for novel treatment options. This evidence concerns the gene MRC2 and cancer.